Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc Class A's next confirmed earnings release is scheduled for October 27, 2026.

As of June 30, 2026, Kiniksa Pharmaceuticals International, plc Class A has 77.98M shares outstanding.

As of June 30, 2026, Kiniksa Pharmaceuticals International, plc Class A maintains a current ratio of 3.90, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Kiniksa Pharmaceuticals International, plc Class A posted a return on equity (ROE) of 14.04, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 12.12 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.36, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 13.81, useful for judging operating efficiency across full business cycles. The company generates approximately 41.59M in revenue per employee across its workforce of 353.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.42 indicates how many times Kiniksa Pharmaceuticals International, plc Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Kiniksa Pharmaceuticals International, plc Class A recorded 586.94M in income tax expense. That works out to an effective tax rate of 29.40, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.00B, leaving 1.41B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Kiniksa Pharmaceuticals International, plc Class A generated 14.69B in revenue and converted that into 1.41B in net income, yielding earnings per share of 17.22. EBITDA reached 1.78B, while operating income came in at 1.75B.

As of June 30, 2026, Kiniksa Pharmaceuticals International, plc Class A holds 9.19B in cash and equivalents against 155.44M in total debt, resulting in a net debt position of -3.07B. Total book value stands at 11.43B, with working capital of 8.69B providing operational flexibility.

Kiniksa Pharmaceuticals International, plc Class A produced 3.23B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -37.18M in capital expenditures, free cash flow totaled 3.19B - equivalent to 41.93 per share.

Over the twelve months ended June 30, 2026, Kiniksa Pharmaceuticals International, plc Class A posted a gross margin of 54.50, reflecting its pricing power and cost economics. The operating margin of 11.92 and net profit margin of 9.59 provide insight into operational efficiency.